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CLINICAL RESEARCH

Efﬁcacy and Safety of Sparsentan Compared
With Irbesartan in Patients With Primary Focal
Segmental Glomerulosclerosis: Randomized,
Controlled Trial Design (DUET)
Radko Komers1, Debbie S. Gipson2, Peter Nelson3, Sharon Adler4, Tarak Srivastava5,
Vimal K. Derebail6, Kevin E. Meyers7, Pablo Pergola8, Meghan E. MacNally1,
Jennifer L. Hunt1, Alvin Shih1 and Howard Trachtman9
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Introduction: Primary focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. There are no US Food and Drug Administrationapproved therapies
for FSGS, and treatment often fails to reduce proteinuria. Endothelin is an important factor in the
pathophysiology of podocyte disorders, including FSGS. Sparsentan is a ﬁrst-in-class, orally active, dualacting angiotensin receptor blocker (ARB) and highly selective endothelin Type A receptor antagonist. This
study is designed to evaluate whether sparsentan lowers proteinuria compared with an ARB alone and has
a favorable safety proﬁle in patients with FSGS.
Methods: DUET is a phase 2, randomized, active-control, dose-escalation study with an 8-week, ﬁxeddose, double-blind period followed by 136 weeks of open-label sparsentan treatment. Patients aged 8 to
75 years with primary FSGS will be randomized to treatment with sparsentan or irbesartan for 8 weeks.
Results: The primary efﬁcacy objective is to test the hypothesis that sparsentan over the dose
range (200 mg, 400 mg, or 800 mg daily) is superior to irbesartan (300 mg daily) in decreasing
the urinary protein-to-creatinine ratio (UPC) from baseline to 8 weeks postrandomization. As
secondary objectives, the trial will evaluate the proportion of patients who achieve prespeciﬁed
targets of UPC reduction, changes in laboratory and quality-of-life indices, and detailed safety analysis. Analyses will be conducted at the end of the double-blind (week 8) and open-label (week 144)
periods.
Discussion: This study will provide important evidence on whether dual ARB and endothelin blockade may
be an effective therapeutic strategy for FSGS and may provide the rationale for next-phase trials.
Kidney Int Rep (2017) 2, 654–664; http://dx.doi.org/10.1016/j.ekir.2017.02.019
KEYWORDS: endothelin receptor antagonist; focal segmental glomerulosclerosis; irbesartan; nephrotic syndrome;
proteinuria; sparsentan
ª 2017 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

ocal segmental glomerulosclerosis (FSGS) is a histopathological pattern of injury seen in some patients who present with nephrotic syndrome or isolated
proteinuria.1 There is a large and heterogeneous group
of known causes of FSGS, which are historically classiﬁed as primary and secondary. Primary FSGS typically has no consistently identiﬁable cause,1 but may
occur as the result of a genetic mutation in a protein
that is essential for normal podocyte structure and/or
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function,2 or may be caused by circulating factors that
injure podocytes and increase glomerular permeability
to protein.3,4 In contrast, secondary FSGS has been
linked to disorders believed to cause maladaptive
injury to glomeruli following the loss of renal parenchyma or systemic metabolic changes,5 and may be
caused by a variety of underlying medical conditions,
such as hypertension, sickle cell anemia, or elevated
body mass index.1,6
Primary FSGS is a rare entity. However, after diabetes and hypertension, primary FSGS is one of the
leading glomerular diseases to cause chronic and endstage renal disease (ESRD), accounting for 5% of incident adult and 12% of incident pediatric ESRD cases.7,8
Nearly 50% of affected patients with nephrotic proteinuria will require renal replacement therapy within
5 to 10 years of diagnosis.9 Primary FSGS occurs in
patients of all ages and races, and the prevalence of
primary FSGS has risen over the last 3 decades in both
children and adults.10–12 It is uncertain whether the
increased prevalence reﬂects an increase in the performance of kidney biopsies or an increase in predisposing risk factors such as low birth weight, use of
nephrotoxic medications, or exposure to environmental
chemicals and viral agents.
Primary FSGS presents as asymptomatic proteinuria
or clinically evident nephrotic syndrome.1,7 Patients
may present with microscopic hematuria and elevated
blood pressure (BP), and often have preserved kidney
function at the time of diagnosis. The diagnosis is
established by a kidney biopsy demonstrating the
characteristic pathologic features of segmental sclerosis
and hyalinosis of the glomerular capillary tuft.13 In the
absence of kidney biopsy, particularly among children,
identiﬁcation of proteinuria and/or a disease-causing
mutation in a podocyte protein in a patient with the
appropriate history (i.e., lack of response to corticosteroids) is often sufﬁcient to make a clinical diagnosis
of FSGS.13
The ﬁrst-line therapy for primary FSGS is often
corticosteroids combined with reninangiotensin
system blockade with angiotensin-converting enzyme
inhibitors (ACEIs) or angiotensin II receptor blockers
(ARBs).6,13,14 In patients who do not respond to
steroids, calcineurin inhibitors (CNIs), including
cyclosporine and tacrolimus, are often prescribed as
second-line therapy.13,15,16 Compared with steroid
monotherapy, use of cyclosporine increases the likelihood of a complete or partial remission of proteinuria in
patients.15,17 Although tacrolimus has replaced cyclosporine as the CNI of choice at many centers, there are
fewer randomized clinical trials speciﬁcally testing this
agent. In patients who do not respond to therapy with
Kidney International Reports (2017) 2, 654–664
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a CNI, there are no established treatment options.13,14
Agents that have been tried with marginal success
include mycophenolate mofetil and rituximab.13,14,18,19
Patients with resistant FSGS are at higher risk for
progressing to ESRD.1,11,20
Attention has also focused on adjuvant, nonimmunosuppressive therapies designed to reduce proteinuria in primary FSGS.21 This basis for practice
derives from evidence that reduction in proteinuria, a
routinely used clinical index of treatment beneﬁt, is
nephroprotective.9,22
Indeed, treatment-associated remission of proteinuria is 1 of the most important independent predictors
of kidney survival.13,23,24 Studies in children and
adults have indicated that there is a doseresponse
relationship between reduction in proteinuria and
clinical outcomes, including renal survival.25,26
Similar to ACEIs or ARBs as adjuvant therapy in
primary FSGS, endothelin (ET) type A (ETA) receptor
antagonists (ERAs) have demonstrated a spectrum of
beneﬁcial effects in a variety of models of glomerular
diseases.27 Consequently, these agents could provide
additive protective effects to ACEIs or ARBs in treating
proteinuric diseases.28 Notably, combining the actions
of angiotensin II and ET antagonists has demonstrated
beneﬁts in experimental models of progressive glomerulosclerosis and tubulointerstitial ﬁbrosis.29,30
Promising results of experimental studies have
motivated clinical development of ERAs for use in
patients with chronic kidney disease.31 Thus far, most
of the study data have been obtained from patients
with diabetic nephropathy. These studies have documented noteworthy additive beneﬁts of ERAs on
reducing proteinuria in patients who undergo optimized treatment with inhibitors of reninangiotensin
system inhibitors (RASIs).32–34 However, further
development of drugs in this new class of nephroprotective agents has been hampered by reports of
adverse effects. Among those, sodium and ﬂuid retention are the most common, resulting in edema and
sometimes heart failure, with the consequence of early
termination of patients from some studies.27,32
More recently, several studies identiﬁed ET as an
important factor in the pathophysiology of podocyte
injury. Speciﬁcally, Buelli et al35 found that ET
precipitated phenotypic and functional changes in
podocytes in vitro consistent with clinical observations
in FSGS, and that treatment of the adriamycin-induced
murine model of FSGS with type A ERAs normalized
renal function and podocyte pathology in vivo. In
another study, adriamycin-induced FSGS and transforming growth factor–b–induced FSGS in mice were
associated with enhanced podocyte production of ET.
655
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This increased ET caused oxidative stress and injury in
adjacent glomerular endothelial cells, leading to reciprocal paracrine injury to podocytes, consistent with
FSGS.36 ET inhibition normalized these alterations and
protected kidneys in these models of glomerular injury.
Together, these studies suggest that, in addition to
their pleotropic antiﬁbrotic, anti-inﬂammatory, and
hemodynamic actions, ERAs may target speciﬁc
molecular pathogenic steps causing FSGS. This new
preclinical evidence provides a strong rationale for the
use of ET receptor blockers in FSGS.
Sparsentan is a ﬁrst-in-class, orally active, dualacting angiotensin type 1 receptor blocker and highly
selective ETA receptor antagonist. It is chemically
similar to the AT1 receptor blocking moiety of irbesartan, an existing ARB, and was originally developed
for the treatment of essential hypertension.28 This
report describes, using the SPIRIT reporting criteria, a
phase 2, randomized, double-blind, active-control,
dose-escalation study (DUET) that will evaluate the
antiproteinuric efﬁcacy and long-term safety of sparsentan, compared with irbesartan, in patients with
primary FSGS, during an 8-week double-blind study
period and a 136-week open-label extension study.
METHODS
Study Participants and Sites
Patients aged 8 to 75 years with biopsy-proven primary
FSGS (idiopathic or due to an identiﬁed mutation) are
eligible to participate in the study. Inclusion and
exclusion criteria for enrollment are presented in
Tables 1 and 2. Because FSGS can occur as a result of
genetic mutations in structural proteins in the podocyte,2 conﬁrmation of a disease-causing mutation in a
podocyte protein will be considered to satisfy the

Table 1. DUET inclusion criteriaa
1

Males and females who are willing and able to provide written informed
consent, with consent signed by patient or legal guardian
US sites: Patients aged 875 years
EU sites: Patients aged 1875 years

2

Biopsy-proven primary FSGS or documentation of a genetic mutation in a
podocyte protein associated with the disease

3

UPC $ 1.0 g/g

4

eGFR > 30 ml/min/1.73 m2

5

Mean seated BP > 100 mm Hg and < 145/96 mm Hg in patients
aged $ 18 years
Mean seated BP for patients aged < 18 years should be > 90/60 mm Hg
and < 95th percentile for age, gender, and height

6

Patients must be on a stable dose of immunosuppressive medication for $ 1
month before randomization. The investigator should not have plans to alter
the regimen during the ﬁrst 8 weeks of the study except to stabilize levels.
Patients who have taken rituximab or cyclophosphamide must have
discontinued the medication $ 3 months before randomization

BP, blood pressure; eGFR, estimated glomerular ﬁltration rate; FSGS, focal segmental
glomerulosclerosis; UPC, urine protein-to-creatinine ratio.
a
Patients must meet all inclusion criteria to be eligible for the study.
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Table 2. DUET exclusion criteriaa
Patients with a medical history of:
FSGS secondary to another condition
Type 1 or uncontrolled type 2 diabetes mellitus
Clinically signiﬁcant cardiac or cerebrovascular disease
Hepatic disease or liver enzyme levels > 2 times the upper limit of normal
Hepatitis B or C infection
HIV infection
Malignancy in the past 5 years, other than adequately treated basal cell or squamous
cell skin cancer
Organ transplantation
Allergic response to any angiotensin II antagonist or endothelin receptor antagonist
Drug or alcohol abuse in the past 2 years
Hematocrit < 27% or hemoglobin < 9 g/dl
Serum potassium > 5.5 mEq/l
Body mass index > 40 kg/m2 for adult patients or in the 99th percentile plus 5 units for
pediatric patients
Women who are pregnant or breastfeeding or who are of child-bearing potential who are
unwilling to use 2 reliable methods of contraception
Patients who have participated in another investigational drug study within 28 days
before screening
Prior exposure to sparsentan
Patients who are unwilling to comply with the study procedures and assessments,
including the ability to swallow the study drug or control capsules
FSGS, focal segmental glomerulosclerosis.
a
A patient who meets any of the criteria will be excluded from the study.

eligibility criterion for the trial in patients who lack
biopsy conﬁrmation of the FSGS diagnosis.
The DUET study has been approved as an ancillary
study of the Nephrotic Syndrome Study Network
(NEPTUNE) observational study,37 and patient enrollment was offered to all sites that are members of the
consortium and obtained institutional review board
(IRB) approval in a timely manner. Approximately 100
patients will be enrolled at an estimated 50 sites in the
United States and Europe. The sites will include
academic hospitals, research centers, and community
nephrology clinics. A list of study sites is available at:
https://clinicaltrials.gov/ct2/show/study/NCT01613118.
Approvals by local IRBs or institutional ethical
committees (IECs) are required before enrollment of
patients at each site.
Study Design and Treatment
A schematic illustration of the study design is presented in Figure 1. Investigators will obtain informed
consent and assent where indicated from patients or
guardians. Patients will be screened to conﬁrm eligibility and will undergo a 2-week washout period
following the discontinuation of any ARB and
ACEI medications. At week 0, a computer-generated
randomization sequence, via an interactive Web
response system, will be used to randomize patients
(3:1) to receive sparsentan or irbesartan. The doubleblind treatment period will last 8 weeks. Patients
who agree to participate in the open-label period of
the study, including those randomized to irbesartan,
will receive sparsentan treatment for an additional
Kidney International Reports (2017) 2, 654–664
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Assess
Inclusion/Exclusion
Criteria

Screening

Washout
Stop RASI

(2 weeks)
Double-Blind Treatment

Sparsentan

Sparsentan

Sparsentan

Irbesartan

(8 weeks)

200 mg

400 mg

800 mg

300 mg

Primary and Secondary Endpoint Analysis

Open-Label Extension

(144 weeks)

Sparsentan
200 mg

Study Close

Sparsentan

Sparsentan

400 mg

800 mg

Sparsentan
200 mg, 400
mg, or 800 mg

Final Analysis

Figure 1. DUET study design and analysis periods. RASI, reninangiotensin system inhibitor.

136 weeks. Patients in either treatment arm will receive
the dose of sparsentan corresponding to their original
randomization cohort. Patients will participate in the
study for a total of 156 to 158 weeks, or approximately
39 months.
Study participants will receive oral sparsentan
200 mg, 400 mg, or 800 mg once daily or irbesartan
300 mg once daily. Patients will be assigned into doseescalating cohorts with incremental safety reviews by
a data monitoring committee (DMC) (Figure 2).
Initially, only patients aged 18 years or older will be
enrolled at the lowest sparsentan dose (200 mg). After
8 patients have completed 4 weeks of treatment, the
DMC will perform a safety review and will determine
whether the study should continue enrollment. If the
safety proﬁle of sparsentan is acceptable, cohort 1 will
begin to enroll pediatric patients (aged 817 years),
and a second cohort comprising adult and pediatric
patients (aged 875 years) will be randomized to
receive sparsentan 400 mg or irbesartan 300 mg. This
randomized, iterative enrollment process will
continue until 5 dosing cohorts are fulﬁlled. Patients
whose body weight is 50 kg or less at week 0 will
receive a 50% reduction in the allocated sparsentan
(i.e., 100 mg, 200 mg, or 400 mg) and irbesartan
(i.e., 150 mg) doses.
Kidney International Reports (2017) 2, 654–664

Indications for dose reduction or patient withdrawal
from the study include general medical or safety reasons, with an emphasis on safety concerns, such as low
or rapidly decreasing estimated glomerular ﬁltration
rate (eGFR; < 30 ml/min), hyperkalemia, ﬂuid retention, edema, or heart failure resistant to diuretic and
other treatment; dose reduction and withdrawal may
be enacted at any visit. The patients who weigh 50 kg
or less and are randomized to cohort 1 (sparsentan 100
mg or irbesartan 150 mg daily during the double-blind
period) and require dose reduction will be withdrawn
from the study, as it is not feasible to reduce the dose
below 150 mg of irbesartan or 100 mg of sparsentan.
Following resolution of signs and/or symptoms
requiring dose reduction, the patient may be reescalated to the originally assigned dose and, if it is
well tolerated, may be continued on that dose per
protocol.
Dose increases will not be permitted during the
double-blind treatment period. Dose increases for lack
of efﬁcacy will be allowed during the open-label period
of the study and may be performed during any visit,
including an unscheduled visit, or implemented via
telephone instruction. The dose may be increased only
to the highest dose level permitted by the DMC at that
time.
657
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Cohort 1
200 mg

Cohort 2
400 mg

Cohort 4
800 mg
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• Randomize adults (aged 8–75 years)
• DMC meets when 8 paents reach 4 weeks of treatment
• Aer DMC agrees the study should connue:
• Begin enrollment of pediatric paents (aged 8–17 years) in cohort 1
• Open cohort 2 for all paents (aged 8–75 years)

• Randomize adult and pediatric paents (aged 8–75 years)
• DMC meets when 8 paents (≥4 of which are >50 kg) reach 4 weeks of treatment
• Aer DMC agrees the study should connue, open cohort 4 and pause cohorts 1 and 2

• Randomize adult and pediatric paents (aged 8–75 years)
• DMC meets when 8 paents (≥4 of which are >50 kg) reach 4 weeks of treatment
• Aer DMC agrees the study should connue, complete enrollment in cohorts 1, 2, and 4

• Aer cohorts 1, 2, and 4 are fully enrolled, open cohorts 3 and 5 to adult and pediatric
paents (≥4 of which are >50 kg)
•
Cohorts
2 and 3 at 400 mg
400 mg, 800 mg
• Cohorts 4 and 5 at 800 mg

Cohorts 3 & 5

Figure 2. Progressive dosing cohorts for the DUET study. The study will progress only after safety review by the data monitoring committee
(DMC).

Sparsentan will be dispensed as 100-mg capsules and
irbesartan as 150-mg tablets overencapsulated in gray
gelatin capsules, both provided in identical kits.
Patients will be instructed to take the appropriate
quantity of capsules for the assigned cohort, orally
once daily before the morning meal. Adherence to
study treatment will be assessed by capsule counts at
each visit. Any unused medication will be returned at
the end of the study.
Concomitant use of RASIs (e.g., ACEIs, ARBs, aliskiren), aldosterone blockers, potassium-sparing diuretics,
interferon-b-1a, rituximab, cyclophosphamide, and
long-term use of nonsteroidal anti-inﬂammatory drugs
are not permitted during the study.
Any changes in the study protocol, such as changes
in the study design, objectives or endpoints, inclusion
and exclusion criteria, and/or procedures (except to
eliminate an immediate hazard) will be implemented by
Retrophin Inc. (San Diego, CA) or its designee. All
protocol changes must be documented in protocol
amendment(s). Protocol amendment(s) must be signed
by Retrophin and approved by the appropriate IRB or
658

IEC before implementation. Any changes in study
conduct that result from a pending amendment will be
considered protocol deviations until IRB/IEC approval
is granted. Documentation of IRB/IEC approval must be
provided to Retrophin or its designee.
Endpoints and Assessments
The primary efﬁcacy endpoint for the double-blind
period is the change in the urinary protein-tocreatinine ratio (UPC) from baseline to week 8. The
secondary efﬁcacy endpoint for the double- blind
period is the proportion of patients in each dose group
that experience a treatment-induced UPC # 1.5 g/g
with a >40% reduction in UPC from baseline at week
8. Tertiary efﬁcacy endpoints include changes from
baseline in 24-hour urinary protein excretion, serum
albumin, serum creatinine levels, eGFR, BP, and lipid
proﬁles. Additionally, changes from baseline in quality
of life using the Pediatric Quality of Life Inventory
(PedsQL v4.0, Mapi Research Trust, Lyon, France)
questionnaire for patients younger than 18 years38,39
and the 36-Item Short Form Health Survey (SF-36)
Kidney International Reports (2017) 2, 654–664
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questionnaire for patients aged 18 years or older will be
evaluated.16,40
Efﬁcacy endpoints for the open-label period include
the changes from week 8 to week 144 (ﬁnal visit) in
UPC, serum creatinine, eGFR, BP, serum albumin,
plasma renin activity, serum endothelin, serum aldosterone, quality of life, and lipid proﬁle parameters.
The proportion of patients experiencing a UPC
ratio # 1.5 g/g with >40% reduction from baseline in
UPC at each visit during open-label sparsentan treatment
will also be evaluated.
The DUET trial will characterize plasma pharmacokinetics (PK) of sparsentan and irbesartan over the
range of doses administered. The PK parameters will be
assessed at week 0 (after the initial dose of sparsentan/
irbesartan) and week 8, and will include maximum and
minimum serum drug concentrations, time of the
maximum and minimum drug concentrations, and area
under the drug concentrationtime curve for speciﬁed
time intervals.
In addition, blood samples collected for biorepository will be assessed for biomarkers that may
become available after the study. These biomarkers
may help to elucidate the mechanisms of FSGS disease
and treatment. Patients may withdraw consent for use
of biorepository samples at any time.
The safety and tolerability of sparsentan will be
assessed by double-blind monitoring of physical
parameters, clinical laboratory tests, electrocardiograms,
and echocardiographic functional parameters, as well as
by monitoring of medications required to control
extracellular ﬂuid volume, edema, and BP. Patients will
be evaluated by investigators for adverse events (AEs) at
each study visit and with each contact outside the clinic
visits (e.g., telephone calls). AEs will be assessed for
severity (mild, moderate, severe) and relationship to
study treatment (none, unlikely, possible, related).
Medications required for controlling ﬂuid volume,
edema, and BP and any dosage changes will be documented. The safety of the study intervention will be
monitored periodically by the DMC as described above.
If 2 or more patients who receive study drug experience
a severe AE within a system organ class that is lifethreatening or results in death, and the severe AE is
deemed possibly related to treatment by the investigator
and/or by Retrophin, the DMC will be notiﬁed within 24
hours. The DMC may decide to immediately stop the
trial, stop recruitment and dosing, or allow continued
recruitment at a lower dose.
During the double-blind treatment period, clinic
visits will occur at weeks 0, 1, 4, and 8. Study visits
during the open-label period are scheduled in 12-week
intervals  14 days. Assessments performed at each
visit are described in Table 3. In addition, telephone
Kidney International Reports (2017) 2, 654–664
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calls will be used to assess safety at weeks 10, 12, 14,
and 148.
Patients who discontinue from the study during
either the double-blind or open-label treatment
periods, for any reason, will undergo a follow-up visit,
and the reason(s) for discontinuation will be documented. If a patient discontinues because of an AE, this
will be noted in the case report form, and any serious
AEs will be followed up until resolution or
stabilization.
Data Management
The DMC will comprise 4 members, inclusive of the
DMC chair, who will be chosen based on expertise in
the study indication and prior indications for which
the study medication was used, clinical trial methods,
and/or the evaluation of laboratory/clinical results.
They will be independent medical reviewers who will
participate without ﬁnancial, intellectual, or other
competing interests. The DMC has 2 purposes through
their safety review: (i) to evaluate the safety of sparsentan and to decide whether dose escalation to the
next cohort should occur; and (ii) to determine the
continuation, modiﬁcation, or termination of the study.
DMC meetings will be organized and decisions documented by the study’s contract research organization
(CTI Clinical Trial & Consulting, Cincinnati, OH). The
DMC charter and DMC documentation of meetings will
be maintained and stored at this contract research
organization.
Study data will be stored in an electronic data capture database, created and maintained by an independent data security ﬁrm (Dependable Global Solutions
Inc., Falls Church, VA). Only site personnel at this facility can enter or change the data. The database will be
programmed to perform edit checks to ensure complete
and accurate data entry, and alerts will be initiated
immediately for out-of-range values and for missing
data on saving the electronic case report form. In
addition, manual edit checks will be created by the
monitors during source document veriﬁcation and the
data managers while cleaning the data. Monitoring,
data management, coding, and pharmacovigilance
activities will be conducted by the contract research
organization, on behalf of Retrophin. Documents
regarding study conduct will be maintained at the
contract research organization, and their standard
operating procedures are followed.
Sites will have access to their data throughout the
duration of the study. After the study is completed, the
database will be decommissioned, and the data, along
with the queries and responses, will be provided to the
sites in a per patient Portable Document Format (PDF)
for only their patients. The raw data output from the
659
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Table 3. DUET study assessment schedule
Screening/ washout
week
L6 to L1

Double-blind treatment
Week 0 Week 1 Week 4

Open-label treatment
Week 8 Weeks 16L132a Week 144

Safety follow-up telephone call
Week 148

Interventionsb
Sparsentan 200 mg













Sparsentan 400 mg













Sparsentan 800 mg













Irbesartan 300 mgc












Sparsentan 200 mg, 400 mg, or 800 mgc
Assessments
Inclusion/exclusion criteria, complete medical history




Quality-of-life questionnaired
Full physical examination































Vital sign measurements









Prothrombin time, INR













Chemistry proﬁle















Complete blood cell count









Lipid panel



Routine urinalysis







Quantitative urinalysis, ﬁrst void







Abbreviated physician examination

24-h Quantitative urinalysis
Renal laboratory testsf



Echocardiogram



12-Lead electrocardiogram



Pharmacokinetic samples









e































g





h












Study medication adherence
Adverse events



































INR, international normalized ratio.
a
Clinic visits at every 12 weeks  14 days. Safety follow-up phone calls will be conducted at weeks 10, 12, and 14.
b
Study medication taken once daily.
c
Patients assigned to irbesartan during the double-blind treatment phase will be offered sparsentan treatment at the dose that they would have received according to the double-blind
dose group in which they were enrolled.
d
36-Item Short Form Health Survey (SF-36) for patients aged $18 years; Pediatric Quality of Life Inventory (PedsQL) for patients aged <18 years.
e
Assessed at weeks 16, 48, and 60 through 144, not all visits.
f
Renin, aldosterone, endothelin, and N-terminal pro B-type natriuretic peptide for patients aged $18 years.
g
Assessed at weeks 16, 24, 48, 72, 96, and 120.
h
Assessed at weeks 16, 48, and 96.

clinical database will be stored at the contract research
organization and transferred to Retrophin. The clinical
data, including the queries and audit trail, will be
provided to Retrophin. The programming for the
tables, listings, and ﬁgures, along with the output, will
also be transferred to Retrophin. At any time before,
during, or after completion of the DUET trial, an audit
may be performed by Retrophin or its designee, or a
representative of a national regulatory agency may
choose to inspect the site. All pertinent study data will
be available for veriﬁcation, audit, or inspection
purposes.
The latest revision of the statistical analysis plan was
ﬁnalized on 27 July 2016 before unmasking.
Statistical Analysis
The full analysis set (FAS) is deﬁned as all randomized
patients who receive at least 1 dose of study drug and
have at least 1 postbaseline efﬁcacy evaluation. The
efﬁcacy evaluable set (EES) is a subset of the FAS and is
deﬁned as all patients who have received at least 1 dose
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of double-blind study drug and have both baseline and
week 8 UPC values. The EES will be used for the
analysis of the primary efﬁcacy endpoint. The per
protocol population is a subset of the EES and excludes
patients with major protocol deviations or medication
compliance of #80% or $120%. Use of speciﬁc disallowed medications and other protocol deviations that
exclude patients from the per protocol analysis set will
be identiﬁed before unblinding the database for the
primary analysis. The safety analysis set consists of all
randomized patients who receive at least 1 dose of
double-blind study drug and have at least 1 postbaseline safety assessment. For each analysis set, patients will be analyzed based on the treatment that they
have received.
Primary Efﬁcacy Endpoint and Analyses

The primary efﬁcacy endpoint analyses will be based
on the EES and will test the hypothesis that sparsentan
is superior to irbesartan in decreasing the UPC in patients with FSGS, as measured by the change from
Kidney International Reports (2017) 2, 654–664
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baseline to 8 weeks’ postrandomization in 24-hour UPC
ratios. To reduce skewness, the natural logarithm will
be used to transform UPC data before analysis. The
primary efﬁcacy endpoint is the change from baseline
to week 8 in log-transformed values of UPC. An analysis of covariance model will be the primary method of
analysis for log (UPC) and other continuous data
(measured as change from baseline to week 8), with
treatment as a ﬁxed effect and baseline value as a
covariate. Results of the analysis will be backtransformed (via exponentiation) to obtain the geometric mean ratio of the UPC values at week 8 to the
baseline value and corresponding 95% conﬁdence
intervals. The values will then be expressed as percentage change in adjusted geometric mean of the UPC
for week 8 relative to baseline. Sparsentan doses or
their combinations will be compared with irbesartan in
the following hierarchical order:







All sparsentan doses (800 mg, 400 mg, and 200 mg)
versus irbesartan
Sparsentan 800-mg and 400-mg dose groups (combined) versus irbesartan
Sparsentan 400-mg dose versus irbesartan
Sparsentan 800-mg dose versus irbesartan

Secondary and Tertiary Endpoints and Analyses

The calculation of the proportion of patients achieving
UPC # 1.5 g/g with 40% reduction in UPC at week 8
will be conducted using the Fisher exact test to
compare sparsentan doses, or combinations of doses,
with irbesartan, in a manner similar to the primary
endpoint. Tertiary endpoints will be based on the EES
population. Analyses of change in 24-hour urine protein excretion from baseline to week 8 will mimic those
of the primary endpoint. Descriptive statistics for the
change from baseline to week 8 in urinary excretion
will be displayed. Analysis of covariance models will
be ﬁtted and used to compare treatments in the same
manner as the primary endpoint analysis.
Analysis of quality-of-life assessments will be based
on the FAS population. Summary statistics per treatment group will be tabulated for SF-36 total scores and
each subdomain, and reported as overall scores
and $5-point improvement in SF-36 physical or mental
component scores. Summary statistics will be provided
for PedsQL scores by visit and the change from baseline to subsequent visits.
Analyses of changes from baseline in serum albumin
and changes from baseline in lipid proﬁle (i.e., total
cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, very-low-density lipoprotein
cholesterol) will be based on the FAS. Data will be presented as descriptive statistics with 95% conﬁdence
intervals for mean change from baseline for all
Kidney International Reports (2017) 2, 654–664

sparsentan doses, mean change from baseline for all
irbesartan doses, and the difference in mean changes
from baseline for all sparsentan and all irbesartan
groups. If conﬁdence intervals indicate that there may
be treatment differences with respect to 1 or more of
these endpoints, the speciﬁc endpoint will be analyzed
further using a mixed-effect model, repeated-measures
analysis.
Subgroup analysis will be performed on patient
subgroups of the EES, including age (patients aged >18
years vs. patients aged #18 years), race, baseline UPC
ratio for nephrotic (UPC $ 3.5 g/g) versus nonnephrotic (UPC < 3.5 g/g) patients, gender, and baseline severity of kidney disease (eGFR > 90, 60–90,
45–60, and 30–45 ml/min/1.73 m2), and BP. Descriptive
statistics and 95% conﬁdence intervals will be calculated for each. Analysis of covariance will be used to
assess the relationship among these prognostic factors,
treatment, cohort, and the change in natural log (UPC)
values.
Plan for Open-Label Analysis

All patients who receive open-label treatment and have
at least 1 safety assessment after the start of the openlabel phase will be included in the Safety Analysis
Set. The FAS analysis set for the open-label phase will
include all patients who receive open-label sparsentan
and have any efﬁcacy assessments after receiving openlabel sparsentan.
In general, tables summarizing open-label efﬁcacy
and safety data will be similar to those produced for the
double-blind period, with the visit schedule extended
to account for long-term follow-up. Duration of total
exposure, average dose, and dose modiﬁcations will be
tabulated in a similar manner.
In particular, the duration of open-label exposure to
sparsentan will be summarized for all patients enrolled
and for groups deﬁned by prior double-blind treatment
(sparsentan or irbesartan). Duration of exposure will be
calculated from the ﬁrst dose (study day 1 for patients
in the sparsentan group) to capture both double-blind
as well as open-label exposure.
Descriptive analyses of the following endpoints
will be presented separately by treatment received
during the double-blind phase: change from baseline
in UPC at each visit during the open-label phase, and
the proportion of patients experiencing a treatmentinduced reduction of UPC ratio # 1.5 g/g with
40% reduction at each visit during open-label
sparsentan treatment. Conﬁdence intervals will be
used to describe changes from baseline in serum
albumin, lipid proﬁle parameters, plasma renin activity, serum endothelin, serum aldosterone, and
quality of life.
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Safety data in the open-label phase, including
physical examination parameters, laboratory tests,
medication use, and incidence of AEs, will be summarized using descriptive statistics. The incidence of AEs
(overall, and by severity and relationship to treatment)
will be tabulated for the full cohort of subjects on openlabel sparsentan. The use of concomitant medications
during the open-label phase will also be summarized.
Clinical laboratory data collected during the
open-label period not mentioned above will be summarized using descriptive statistics, including tabulations of mean and mean change values at each study
visit, and frequency tables indicating the of number
subjects with values classiﬁed as below, within, or
above-normal range at each visit. Graphs of average
values ( SE) will be plotted by treatment group
including the group analysis based on prior doubleblind irbesartan versus sparsentan treatment at all
study visits, beginning from the start of open-label
sparsentan until the last assessment during the
open-label period.
Vital signs and electrocardiographic data measured
during the open-label treatment will be presented
descriptively at each study visit, with patients grouped
by prior treatment (sparsentan or irbesartan). Tabulations will be similar to those produced for the doubleblind period, with an extended-visit schedule.
Due to the relatively low numbers of patients per
site, no site-speciﬁc analyses will be conducted, and
no adjustments will be made for individual sites. All
analyses will be performed using pooled data across all
study sites.
Unblinding Considerations

The only planned analysis of unblinded data during
the ongoing study is for the purpose of the DMC’s
review of accumulating safety data. A limited number
of preidentiﬁed individuals from the contract research
organization responsible for the interim analysis will
have access to unblinded data to prepare a safety
output for the DMC review; this team will be independent of the project team and will not have access to
ongoing data management activities. If a patient’s
information needs to be unblinded for a medical
emergency, the sites have an interactive Web response
system unblinding manual that instructs them how to
unblind a patient after consulting with the sponsor. If
an event requires unblinding to comply with regulatory reporting requirements for a suspected, unexpected serious adverse reaction, this process is outlined
in the safety management plan for the study. After
database lock for the study, appropriate study team
members will be unblinded, as outlined in a preestablished unblinding plan.
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Sample Size and Power Calculations

The study plan is to enroll 100 patients at a 3:1
sparsentan-to-irbesartan ratio, yielding 15, 30, and 30
patients in the sparsentan 200-mg, 400-mg, and 800-mg
groups, respectively, and 25 patients in the irbesartan
group. A cohort may be expanded to enroll additional
patients (no more than 2 times the original size), and/or
additional cohorts at doses $ 800 mg may be added to
better assess the safety and tolerability proﬁle of
sparsentan.
Based on published observations in proteinuric
patients with type 2 diabetes32–34 treated with baseline
RASI and add-on ET receptor antagonist, the mean
reduction in UPC (expressed as the ratio of geometric
means) is expected to be at least 20% greater with
sparsentan compared with irbesartan (i.e., mean
reduction of 40% vs. 20%). This difference represents
a geometric mean ratio of 2.0. To calculate the study
power, ratios were explored in the range of 1.25 to 2.5,
in the original units, using a Student t test (2-sided
a ¼ 0.05) of log-transformed UPC values for sparsentan and irbesartan. Under a range of assumptions for
the variability in UPC, the study has approximately
64% to 76% power to demonstrate the expected difference between sparsentan and irbesartan (e.g., 40%
vs. 20% reduction in UPC). The study power will be
adequate if the high doses of sparsentan have a marked
effect on UPC (i.e., more than double the average
percent reduction compared with irbesartan), but
smaller effects may not reach statistical signiﬁcance. In
this scenario, analysis of combined sparsentan dose
groups compared with the irbesartan group (n ¼ 25)
will provide enhanced power to detect the same difference in UPC.
Strategies for Achieving Adequate Participant
Enrollment
As with all rare diseases, recruitment for clinical trials
is a challenge. Recruitment for DUET will rely on the
existing pool of patients at individual participating
sites. To enhance enrollment, information about the
trial will be disseminated via patient advocacy groups
(e.g., NephCure Kidney International, King of Prussia,
PA), recruitment vendors (e.g., Matthew’s Medical
Group), social media, and a study website.
DISCUSSION
Currently there is no US Food and Drug Administrationapproved therapy for FSGS. This unmet clinical need has put a premium on the development of safe,
well-tolerated nephroprotective agents. Initial experience with ET antagonists as derived from the results of A
Study of Cardiovascular Events in Diabetes (ASCEND)
trial in diabetic nephropathy32 has been disappointing
Kidney International Reports (2017) 2, 654–664
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because of the clinical limitations and disabling AEs,
such as worsening edema and anemia, that prevented
widespread application despite demonstrable reduction
in proteinuria. More recent short-term studies with
another ERA, atrasentan, have shown a more favorable
proﬁle at lower dose ranges together with signiﬁcant
add-on effect on proteinuria reduction in type 2 diabetic
patients.33,34 However, the long-term nephroprotective
potential of atrasentan is not known and is currently
being established in an ongoing Study of Diabetic Nephropathy with Atrasentan (SONAR) trial in type 2
diabetic patients with proteinuria.
DUET is the ﬁrst study to evaluate the antiproteinuric effects and long-term safety of a dual
angiotensin II and ET 1 antagonist in the nondiabetic
context of primary FSGS. Evaluation of the effects on
proteinuria will be speciﬁcally important in primary
FSGS, a podocytopathy in which changes in proteinuria are critical in disease pathogenesis and course.
It is important to recognize the potential limitations
of the DUET trial. The intended sample size is modest,
and the study cohort may not reﬂect the diversity of
patients affected by FSGS. Although participating sites
are encouraged to recruit every eligible patient, which
should include a representative distribution of patient
demography, the study sample size will not support
ancestry-stratiﬁed analysis. The protocol does not
include assessment of proteinuria after discontinuation
of drug treatment; therefore, it will not be possible to
deﬁnitively ascertain the degree to which beneﬁcial
effects of sparsentan endure beyond the treatment
period. The double-blind treatment phase is only
8 weeks in duration. However, as outlined above, the
option for patients to participate in the open-label
phase will enable collection of data to assess the
effect of sparsentan on proteinuria for a more extended
period and to clarify the safety proﬁle. Potential
unintended consequences of sparsentan use include
exacerbation of edema, increased incidence of anemia
and heart failure, and adverse effects on acidbase
balance. Careful follow-up of the study cohort with
surveillance for these and other unanticipated adverse
effects will be essential before sparsentan can be
considered for routine use in patients with FSGS.
Overall, this phase 2, randomized, double-blind,
active control FSGS clinical trial will test the efﬁcacy
and safety of the dual ARB-ETA compared with ARB
alone for the control of FSGS in children and adults. In
addition to double-blind evaluation of antiproteinuric
effects of sparsentan over the period of 8 weeks, the
long-term, open-label treatment will provide information on sparsentan safety and clinically relevant outcomes, namely prevention of increased serum
creatinine concentration and progression to ESRD.
Kidney International Reports (2017) 2, 654–664

Sparsentan may be the ﬁrst agent acting as an endothelin antagonist that is suitable for extended use as a
nephroprotective agent. This would be especially
notable in patients with a glomerular disease such as
FSGS who are susceptible to edema as part of their
clinical phenotype.
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